TAZVERIK
PeakSMtazemetostat
NDAORALTABLETPriority Review
Approved
Jan 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAZVERIK (tazemetostat) is an oral small molecule EZH2 inhibitor approved in January 2020 for treating certain hematologic malignancies, particularly follicular lymphoma and other EZH2-mutant tumors. It represents a targeted epigenetic therapy addressing a specific molecular driver in cancer cells.
$19MPart D
Peak11.9 years to LOEProduct is at peak commercial stage with modest Medicare spending, indicating stable but niche market positioning and likely a focused specialist sales team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies
Started Jun 2026
0Follicular Lymphoma
Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Started Sep 2025
24 enrolled
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation
Started Sep 2025
0Follicular LymphomaRefractory Follicular Lymphoma
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Started Dec 2024
0LymphomaPeripheral T Cell LymphomaAngioimmunoblastic T-cell Lymphoma+2 more
Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma
Started Nov 2023
23 enrolled
Follicular Lymphoma
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.